Loading company
$33.95+0.2%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 12, 2026
Past performance
- 1W
- +1.5%
- 1M
- +13.4%
- 3M
- +23.3%
- 6M
- +25.5%
- 1Y
- +8.5%
- 5Y
- -36.4%
$33.95+0.2%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 12, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $8.4M | $72.2M | -88.41% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Galapagos NV has no earnings call transcript available.
“At ASH, we look forward to sharing results from patients enrolled in company-sponsored trials, which we believe will further characterize the differentiated efficacy and safety profile of gamgertamig and its potential as a first- and best-in-class T-cell engager in autoimmune disease,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Galapagos NV filed on November 12, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.